INVESTOR RELATIONS

PRESS RELEASES

12-Nov-2002 AMARIN’S PARTNER TANABE SUBMITS DCV MORPHINE ONCE DAILY FORMULATION TO MHLW IN JAPAN
28-Oct-2002 AMARIN CORPORATION ANNOUNCES ENCOURAGING PRELIMINARY RESULTS OF LAX-101 PIVOTAL STUDY IN HUNTINGTON'S DISEASE
28-Oct-2002 AMARIN CORPORATION REPORTS THIRD QUARTER 2002 FINANCIAL RESULTS
24-Oct-2002 AMARIN CORPORATION PLC ANNOUNCES THIRD QUARTER 2002 EARNINGS CONFERENCE CALL
30-Sep-2002 AMARIN CORPORATION ANNOUNCES RESEARCH COLLABORATION WITH CELLGATE INC. TO STUDY CONTROLLED RELEASE AND TARGETED DELIVERY OF ORAL MEDICINES
23-Sep-2002 AMARIN CORPORATION ANNOUNCES APPOINTMENT OF VICE PRESIDENT, REGULATORY AFFAIRS
19-Aug-2002 AMARIN CORPORATION PLC APPOINTS STEFAN OHLSSON MANAGING DIRECTOR OF AMARIN DEVELOPMENT AB
1-Aug-2002 AMARIN CORPORATION PLC APPOINTS BILL MASON AS DIRECTOR
24-Jul-2002 AMARIN CORPORATION REPORTS SECOND–QUARTER RESULTS
23-Jul-2002 AMARIN CORPORATION RESTRUCTURES LOAN AGREEMENT WITH ELAN
18-Jul-2002 AMARIN CORPORATION PLC ANNOUNCES SECOND QUARTER 2002 EARNINGS CONFERENCE CALL
8-Jul-2002 AMARIN CORPORATION CLOSES TRANSACTION TO ACQUIRE U.S. RIGHTS TO PERMAX®
31-May-2002 AMARIN CORPORATION TO PRESENT AT UBS WARBURG GLOBAL SPECIALTY PHARMACEUTICALS CONFERENCE, JUNE 5, 2002
23-May-2002 AMARIN CORPORATION ANNOUNCES ACCEPTANCE FOR FILING OF NEW DRUG APPLICATION FOR ZELAPAR™ BY US FDA
16-May-2002 AMARIN CORPORATION ANNOUNCES DRUG RESEARCH AGREEMENT WITH EIFFEL TECHNOLOGIES LTD. TO IMPROVE ORAL DRUG DELIVERY
14-May-2002 AMARIN CORPORATION REPORTS FIRST-QUARTER SALES AND EARNINGS
9-May-2002 AMARIN CORPORATION PLC ANNOUNCES FIRST QUARTER 2002 EARNINGS CONFERENCE CALL
8-May-2002 AMARIN CORPORATION EXERCISES PURCHASE OPTION TO ACQUIRE U.S. RIGHTS TO PERMAX®
3-Apr-2002 AMARIN CORPORATION ANNOUNCES PARTIAL CONVERSION OF CONVERTIBLE PREFERENCE SHARES BY ELAN
28-Mar-2002 AMARIN CORPORATION TO PRESENT AT BANC OF AMERICA SECURITIES HEALTHCARE CONFERENCE
Page 1 of 2